The pharmaceutical industry confronts a pivotal moment as the imperative to integrate sustainability throughout supply chains gains momentum. Amid shifting paradigms, companies are increasingly aware that business success is no longer measured solely in financial terms. Today's corporate climate
In a significant expansion of its life sciences portfolio, global science and technology leader Merck has announced a definitive agreement to purchase Mirus Bio for a staggering $600 million. Mirus Bio, a pioneering life sciences company, specializes in developing transfection reagents, a
The landscape of biopharmaceutical manufacturing in Ireland has recently welcomed an impressive addition with the inauguration of the National Institute for Bioprocessing Research and Training's (NIBRT) new facility. This state-of-the-art establishment in Dublin, conceived with a robust €21 million
In a significant move aimed at boosting the development of cell and gene therapies, Bionova Scientific, a part of the Asahi Kasei Group, has announced an ambitious $100 million investment. This investment will see the creation of a new state-of-the-art plasmid DNA (pDNA) production facility in The
In the rapidly-changing environment of the pharmaceutical industry, the innovative stride of Pharma 4.0 heralds a new era of drug production. This pivotal shift to smart manufacturing aligns with the principles of Industry 4.0, embedding digitalization and cutting-edge technology to meet the
AstraZeneca, the renowned pharmaceutical giant, has unveiled plans to invest $1.5 billion in a cutting-edge antibody drug conjugate (ADC) manufacturing facility in Singapore, marking a significant milestone in the company's history. The state-of-the-art factory is poised to become operational in
